我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
798
76 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
12
1.5%
已完成
423
53.0%
尚未招募
64
8.0%
招募中
159
19.9%
终止
56
7.0%
Unknown
62
7.8%
撤回
22
2.8%
暂无批准数据
- A Phase 2 trial of Sanofi's lixisenatide demonstrated the GLP-1 agonist's potential to halt motor symptom progression in Parkinson's disease patients over 12 months. - The LixiPark study revealed patients receiving lixisenatide maintained stable motor function scores, while the placebo group experienced a 3.04-point decline in MDS-UPDRS III scores. - The findings, published in the New England Journal of Medicine, suggest a possible breakthrough in neuroprotective treatment for Parkinson's, though longer studies are needed to confirm clinical significance.
